Abstract 1013
Background
Carcinoma of unknown primary (CUP) is a heterogeneous entity of malignant epithelial tumors. In general, CUP follows an aggressive biological and clinical behavior. There is generally limited information regarding this issue.
Methods
All patients categorized as having CUP who attended the department of clinical oncology, Menoufia University from January 2013 to December 2015 were included in the study. The patients’ features, investigations and clinical outcomes were collected. Also, time to progression (TTP) and overall survival (OS) were calculated.
Results
The study included 103 patients representing about 2.2% of the total number of patients visited clinical oncology department outpatients’ clinic during the same period. Most of the patients were males, the mean age of the patients was 58 years, pain was the most common presenting symptom, and adenocarcinoma was the most common reported pathological subtype. Only 50.5% of the patients were fit to receive platinum combination chemotherapy. The median TTP was 2 months and the median OS was 3 months. Age, performance status & presenting symptom had statistically significant relation with TTP. While, the baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.
Conclusions
Carcinomas of unknown primary origin are not uncommon tumors in clinical oncology department, Menoufia University with wide varieties of clinical presentations. Baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
905 - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy
Presenter: Umesh Velu
Session: Poster display - Cocktail
Resources:
Abstract
1060 - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?
Presenter: Kartika Taroeno-Hariadi
Session: Poster display - Cocktail
Resources:
Abstract
1148 - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali
Presenter: Anak Agung Lestari
Session: Poster display - Cocktail
Resources:
Abstract
400 - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Norikazu Masuda
Session: Poster display - Cocktail
Resources:
Abstract
801 - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer
Presenter: Mohamed Elbaiomy
Session: Poster display - Cocktail
Resources:
Abstract
1014 - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®
Presenter: Quanying Zhang
Session: Poster display - Cocktail
Resources:
Abstract
1138 - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s
Presenter: Yunjie He
Session: Poster display - Cocktail
Resources:
Abstract
145 - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.
Presenter: Abhishek Anand
Session: Poster display - Cocktail
Resources:
Abstract
804 - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer
Presenter: John Robertson
Session: Poster display - Cocktail
Resources:
Abstract
1154 - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients
Presenter: Sung Soo Kang
Session: Poster display - Cocktail
Resources:
Abstract